



EDUCATIONAL RESOURCES

Nausea & Vomiting: A Palliative Perspective

Ellen Fulp, PharmD, MSPC, BCGP
Director of Pharmacy Education,
AvaCare, Inc.

 PALLIATIVE CARE



ACHCU IS A BRAND OF ACCREDITATION COMMISSION *for* HEALTH CARE



Objectives

- Review nausea and vomiting, including symptom progression during illness trajectories
- Discuss nausea and vomiting etiologies and associated treatment options
- Highlight education and management of nausea and vomiting during advanced illnesses

Nausea

- Unpleasant sensation of being about to vomit
- Back of the throat and epigastrium
- Non-observable
- Autonomic symptoms
 - Pallor, cold sweat, salivation, tachycardia
- Anorexia, loss of appetite
- May occur alone or in combination with additional symptoms
 - Vomiting, dyspepsia, or gastrointestinal symptoms
- Patient description

Vomiting

- Expulsion of gastric contents through the mouth or nose
- Cause: forceful and sustained contractions of abdominal muscles and diaphragm
- Metabolic disturbances, malnutrition, electrolyte imbalances
- Interruptions in treatments
- Patient description


Nausea and Vomiting: Pathophysiology

CTZ: Neurotransmitters

Vestibular System: Motion

Cortical Centers: Anxiety, Brain

Vagus (+ other) Nerve: Gastroparesis



Patient Assessment

- Initial and ongoing
- Pathophysiology
- History
 - Pattern, triggers, pain, dysphagia, thirst, hiccups, heartburn, constipation
- Physical exam
- Diagnostic testing
- Differential diagnoses

Nausea and Vomiting: Malignant Disease

- Etiology
- Multifactorial
- Simultaneously vs. sequentially

Anti-tumor
treatment

Acute
complication

Gastroparesis

Drug-
induced
constipation

Nausea and Vomiting: Malignant Disease

Highly Emetogenic Therapy

- 5-HT₃ antagonists, corticosteroids, neurokinin-1 (NK1) antagonists

Moderately Emetogenic Therapy

- 5-HT₃ antagonists, corticosteroids

Low Emetogenic Risk

- Corticosteroids

Nausea & Vomiting: Common Causes

Chemical & Drug Induced

- Electrolyte imbalance
- Organ failure
- Opioids
- Antibiotics
- Anticonvulsants

Gastric Stasis

- Stomach cancer
- Ascites
- Opioids
- Anticholinergics
- Ulcers

GI Obstruction & Irritation

- Cancer related
- Ulcers
- Distension or compression
- Delayed gastric emptying
- Obstruction
- Constipation
- Chemo/radiation
- Infection
- Medications

Increased Intracranial Pressure

- Cerebral edema
- Tumor
- Bleeding
- Meningeal disease

Vestibular

- Opioids
- Motion sickness

Psychological

- Anxiety
- Anticipatory

Nausea & Vomiting: Treatment



Nonpharmacologic Therapy

- Self-management techniques
- Complementary and alternative medicine
 - Music, aromatherapy, massage, exercise, cognitive distraction
- Acupuncture
- Desensitization
- Hypnosis

Pharmacologic Therapy

Prokinetics

Dopamine
Antagonists

Antihistamines

5-HT₃
Antagonists

Corticosteroids

Benzodiazepines

Anticholinergics

Octreotide

NK1 Antagonists

Cannabinoids*

Prokinetic Agents

- Stimulate motility (upper GI tract)
 - Four potential MOA
 - 5-HT₄ receptor agonist (gut), 5-HT₃ antagonist, motilin receptor activation, dopaminergic antagonist
 - Extrapyramidal symptoms
 - Gastric stasis
 - Dose reductions
 - Contraindications
 - Adverse effects
- Class Example: Metoclopramide



Dopamine Receptor Antagonists

- Antiemetic doses typically lower than antipsychotic doses
- Dopamine blockade in CTZ
- Many have broad spectrums of activity
 - Histamine, muscarinic, serotonergic, alpha-adrenergic receptor antagonism
- Side effect profile
- Class Example: Haloperidol
- Class Example: Prochlorperazine
- Class Example: Olanzapine



Antihistamines

- H1 receptor blockade in vomiting center, CTZ, vestibular nuclei
- Nausea and vomiting associated with movement, dizziness, vertigo
- Adverse effects
- Class Example: Promethazine
- Class Example: Hydroxyzine



Selective 5-HT₃ Receptor Antagonists

- Antagonize 5-HT₃ receptors centrally in the CTZ and peripherally in the gut wall
- Prevention of chemotherapy-induced and radiation induced nausea and vomiting
- Adverse effects
- Class Example: Ondansetron



Corticosteroids

- Mechanism poorly understood
 - Multi-drug prophylactic regimens
 - Useful: increased intracranial pressure, hypercalcemia of malignant disease
 - Obstruction
 - Adverse effects: long-term, short-term
- Class Example: Dexamethasone



Benzodiazepines

- Gamma-aminobutyric acid (GABA) effects
 - Anticipatory nausea
 - Anxiolytic
 - Combination therapy
 - Adverse effects
- Class Example: Lorazepam



Anticholinergic Agents

- Muscarinic receptor antagonists
- Nausea associated with movement or dizziness
- Refractory nausea (bowel obstruction)
- Formulation flexibility
- Adverse effects
 - Avoid/use caution in elderly patients
- Class Example: Scopolamine



NK1 Receptor Antagonists

- Prevent substance P from binding to NK1 receptors
- Acute and delayed prevention of chemotherapy-induced nausea and vomiting
- Combination therapy
- Class Example: Aprepitant



Somatostatin Analogs

- Acts like somatostatin- inhibits hormones including growth hormone, glucagon, insulin, LH
 - Inhibits gastric, pancreatic and intestinal secretions
 - Reduces GI motility
 - Helpful in high volume emesis
 - Intestinal obstruction(s)
 - Adverse effects
- Class Example: Octreotide



Cannabinoids

- Cannabinoid receptors in brainstem
 - Mu opioid receptors
 - Chemotherapy-induced nausea and vomiting
 - Legality
 - Adverse effects
- Class Example: Dronabinol
 - Class Example: Marijuana



Nausea & Vomiting: Education




Self-Management Strategies



Refractory Nausea & Vomiting

- Combination therapy
- Patient suffering
- Palliative sedation



References

- Collett D, Chow K. “Nausea and Vomiting.” Oxford Textbook of Palliative Nursing, Ferrell BR, Paice JA, Oxford University Press. 2019.
- Del Fabbro, E. Assessment and management of nausea and vomiting in palliative. In: UpToDate, Post TW (Ed), UpToDate, Waltham, MA. Accessed September 2022.
- Aapro M, Molassiotis A, Dicato M, et al. The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER). *Ann Oncol* 2012; 23:1986.
- Rhodes VA, McDaniel RW. Nausea, vomiting, and retching: complex problems in palliative care. *CA Cancer J Clin* 2001; 51:232.
- Atkinson SR. Olanzapine for intractable nausea and vomiting in palliative care patients not receiving chemotherapy. *J Palliat Med* 2014; 17:503.
- Hardy J, Skerman H, Glare P, et al. A randomized open-label study of guideline-driven antiemetic therapy versus single agent antiemetic therapy in patients with advanced cancer and nausea not related to anticancer treatment. *BMC Cancer* 2018; 18:510.



EDUCATIONAL RESOURCES

Thank you

Ellen Fulp, PharmD, MSPC, BCGP
ellenf@avacare.biz

 PALLIATIVE CARE



ACHCU IS A BRAND OF ACCREDITATION COMMISSION *for* HEALTH CARE

